Brought to you by 
Merck Ventures and Merck KGAA spin out iOnctura; provide seed funding
20 Dec 2022
Executive Summary
Merck KGaA’s venture arm Merck Ventures has spun out a new immuno-oncology company named iOnctura SA, and provided the start-up with an undisclosed amount of seed funding.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck Ventures and Merck KGAA spin out iOnctura; provide seed funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice